loading
Regeneron Pharmaceuticals Inc stock is traded at $589.48, with a volume of 1.44M. It is down -1.45% in the last 24 hours and up +5.09% over the past month. Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
See More
Previous Close:
$598.16
Open:
$602.35
24h Volume:
1.44M
Relative Volume:
1.27
Market Cap:
$61.41B
Revenue:
$14.21B
Net Income/Loss:
$4.46B
P/E Ratio:
14.86
EPS:
39.68
Net Cash Flow:
$3.56B
1W Performance:
+1.56%
1M Performance:
+5.09%
6M Performance:
-15.83%
1Y Performance:
-50.37%
1-Day Range:
Value
$585.50
$610.45
1-Week Range:
Value
$570.39
$610.45
52-Week Range:
Value
$476.49
$1,211.20

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Name
Name
Regeneron Pharmaceuticals Inc
Name
Phone
(914) 847-7000
Name
Address
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Name
Employee
15,207
Name
Twitter
@regeneron
Name
Next Earnings Date
2025-08-01
Name
Latest SEC Filings
Name
REGN's Discussions on Twitter

Compare REGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-14-25 Initiated Rothschild & Co Redburn Buy
Jun-30-25 Downgrade Argus Buy → Hold
May-30-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
May-30-25 Downgrade Wells Fargo Overweight → Equal Weight
May-14-25 Upgrade Citigroup Neutral → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Feb-05-25 Upgrade Leerink Partners Market Perform → Outperform
Jan-16-25 Downgrade UBS Buy → Neutral
Dec-10-24 Resumed BofA Securities Underperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Neutral
Sep-24-24 Downgrade Leerink Partners Outperform → Market Perform
Mar-12-24 Initiated Bernstein Outperform
Jan-12-24 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Nov-03-23 Upgrade Raymond James Mkt Perform → Outperform
Aug-21-23 Upgrade Canaccord Genuity Hold → Buy
Aug-21-23 Reiterated Oppenheimer Perform
Jun-28-23 Downgrade Canaccord Genuity Buy → Hold
Mar-27-23 Upgrade SVB Securities Market Perform → Outperform
Mar-24-23 Upgrade Jefferies Hold → Buy
Mar-23-23 Upgrade Raymond James Underperform → Mkt Perform
Jan-30-23 Upgrade Cowen Market Perform → Outperform
Jan-20-23 Upgrade JP Morgan Neutral → Overweight
Oct-26-22 Downgrade Raymond James Mkt Perform → Underperform
Oct-17-22 Downgrade Evercore ISI Outperform → In-line
Sep-09-22 Upgrade Jefferies Underperform → Hold
Sep-09-22 Upgrade Morgan Stanley Equal-Weight → Overweight
Jul-25-22 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-06-22 Initiated Jefferies Underperform
May-23-22 Initiated SVB Leerink Outperform
Jan-05-22 Downgrade BofA Securities Neutral → Underperform
Jan-03-22 Upgrade Bernstein Mkt Perform → Outperform
Dec-15-21 Downgrade Bernstein Outperform → Mkt Perform
Dec-09-21 Resumed Wells Fargo Overweight
Dec-07-21 Resumed Cowen Market Perform
Dec-06-21 Initiated Goldman Buy
Nov-19-21 Resumed BMO Capital Markets Outperform
Nov-05-21 Downgrade The Benchmark Company Buy → Hold
Jun-29-21 Initiated H.C. Wainwright Buy
Jan-25-21 Upgrade BMO Capital Markets Market Perform → Outperform
Jan-13-21 Upgrade The Benchmark Company Hold → Buy
Jan-08-21 Upgrade Citigroup Neutral → Buy
Oct-05-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Aug-20-20 Downgrade The Benchmark Company Buy → Hold
Jul-09-20 Upgrade SunTrust Hold → Buy
May-26-20 Upgrade Wells Fargo Equal Weight → Overweight
Apr-28-20 Downgrade Citigroup Buy → Neutral
Apr-17-20 Upgrade The Benchmark Company Hold → Buy
Apr-08-20 Initiated The Benchmark Company Hold
Mar-31-20 Initiated Wolfe Research Peer Perform
Feb-27-20 Initiated Barclays Overweight
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Feb-26-20 Downgrade Robert W. Baird Outperform → Neutral
Feb-25-20 Upgrade Jefferies Hold → Buy
Feb-11-20 Upgrade Argus Hold → Buy
Dec-24-19 Initiated Raymond James Mkt Perform
Dec-16-19 Downgrade Evercore ISI Outperform → In-line
Dec-13-19 Upgrade Credit Suisse Neutral → Outperform
Nov-12-19 Initiated SunTrust Hold
Nov-07-19 Upgrade Citigroup Neutral → Buy
Oct-17-19 Resumed BofA/Merrill Neutral
Sep-23-19 Upgrade Guggenheim Neutral → Buy
View All

Regeneron Pharmaceuticals Inc Stock (REGN) Latest News

pulisher
Aug 20, 2025

Regeneron Surges on FDA Delay as $0.77B Volume Ranks in Top 500 - AInvest

Aug 20, 2025
pulisher
Aug 20, 2025

FDA Pushes Back Eylea HD Review; Regeneron Still Gains - Yahoo Finance

Aug 20, 2025
pulisher
Aug 20, 2025

Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 20, 2025
pulisher
Aug 20, 2025

Scholar Rock jumps following Regeneron Eylea update - Seeking Alpha

Aug 20, 2025
pulisher
Aug 20, 2025

Element Capital Management LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Regeneron's Eylea injection review dates delayed by FDA (REGN) - Seeking Alpha

Aug 20, 2025
pulisher
Aug 20, 2025

Aberdeen Group plc Acquires 56,746 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Fox Run Management L.L.C. Buys Shares of 1,734 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Regeneron Pharmaceuticals Announces FDA Extension for EYLEA HD® Regulatory Submissions to Q4 2025 - Quiver Quantitative

Aug 20, 2025
pulisher
Aug 20, 2025

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions - Stocktwits

Aug 20, 2025
pulisher
Aug 20, 2025

FDA Extends Review Timeline: Regeneron's EYLEA HD Faces Q4 2025 Decision for Expanded Uses - Stock Titan

Aug 20, 2025
pulisher
Aug 20, 2025

RWA Wealth Partners LLC Decreases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Qtron Investments LLC - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

500 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Corient IA LLC - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

American Century Companies Inc. Purchases 14,921 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Independent Advisor Alliance Buys 472 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 20, 2025
pulisher
Aug 19, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Public Sector Pension Investment Board - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

Kovitz Investment Group Partners LLC Buys 3,090 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

Cambiar Investors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

Ethic Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Fjarde AP Fonden Fourth Swedish National Pension Fund - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

Gulf International Bank UK Ltd Sells 2,097 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 19, 2025
pulisher
Aug 19, 2025

National Pension Service Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 19, 2025
pulisher
Aug 18, 2025

Sienna Gestion Has $5.65 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Regeneron Stock Slumps as Trading Volume Plunges 31% to 440M Ranking 207th in U.S. Activity - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

85,929 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Tocqueville Asset Management L.P. - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Leo Keeps On Profitable Path With Solid H1 Sales Growth - insights.citeline.com

Aug 18, 2025
pulisher
Aug 18, 2025

Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™ - GlobeNewswire Inc.

Aug 18, 2025
pulisher
Aug 18, 2025

State of New Jersey Common Pension Fund D Trims Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Dimensional Fund Advisors LP Sells 15,838 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Prudential PLC - MarketBeat

Aug 18, 2025
pulisher
Aug 18, 2025

Connor Clark & Lunn Investment Management Ltd. Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 18, 2025
pulisher
Aug 17, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by E Fund Management Co. Ltd. - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

1,038 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by S Bank Fund Management Ltd - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

Tokio Marine Asset Management Co. Ltd. Has $9.55 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

Russell Investments Group Ltd. Has $93.08 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

Resona Asset Management Co. Ltd. Acquires 1,225 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 17, 2025
pulisher
Aug 17, 2025

How volatile is Regeneron Pharmaceuticals Inc. stockTrade Volume Report & Technical Confirmation Alerts - thegnnews.com

Aug 17, 2025
pulisher
Aug 17, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Strong-Buy at Redburn Atlantic - MarketBeat

Aug 17, 2025
pulisher
Aug 16, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Rothschild & Co Redburn - MarketBeat

Aug 16, 2025
pulisher
Aug 16, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Invesco Ltd. - MarketBeat

Aug 16, 2025
pulisher
Aug 15, 2025

Regeneron Pharmaceuticals Inc. Building a Base Near SupportMarket Performance Summary & Growth Oriented Trading Recommendations - thegnnews.com

Aug 15, 2025
pulisher
Aug 15, 2025

Cary Street Partners Financial LLC Sells 959 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 15, 2025
pulisher
Aug 15, 2025

Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Potential Game Changer - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Regeneron’s Phase 3 Study on Garetosmab: A Potential Game-Changer for FOP Treatment - TipRanks

Aug 15, 2025
pulisher
Aug 15, 2025

Can Eylea HD and Dupixent Profits Revive Regeneron Stock? - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Mizuho Securities USA LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat

Aug 15, 2025
pulisher
Aug 15, 2025

Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $812.00 Price Target at Truist Financial - MarketBeat

Aug 15, 2025

Regeneron Pharmaceuticals Inc Stock (REGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Regeneron Pharmaceuticals Inc Stock (REGN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
McCourt Marion
EVP Commercial
Nov 01 '24
Option Exercise
381.40
1,000
381,400
13,931
McCourt Marion
EVP Commercial
Nov 01 '24
Sale
844.61
1,000
844,610
12,931
$454.38
price down icon 2.82%
$660.00
price down icon 0.56%
biotechnology ONC
$313.67
price down icon 0.10%
$131.88
price down icon 0.54%
$110.88
price up icon 0.10%
Cap:     |  Volume (24h):